King's Research Portal

DOI:

[10.1016/j.jad.2016.02.060](https://doi.org/10.1016/j.jad.2016.02.060)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Stubbs, B., Vancampfort, D., Veronese, N., Solmi, M., Gaughran, F., Manu, P., Rosenbaum, S., De Hert, M., & Fornaro, M. (2016). The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis. *Journal of Affective Disorders*. <https://doi.org/10.1016/j.jad.2016.02.060>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis

Brendon Stubbs, Davy Vancampfort, Nicola Veronese, Marco Solmi, Fiona Gaughran, Peter Manu, Simon Rosenbaum, Marc De Hert, Michele Fornaro

PII: S0165-0327(15)31193-9
DOI: <http://dx.doi.org/10.1016/j.jad.2016.02.060>
Reference: JAD8078

To appear in: *Journal of Affective Disorders*

Received date: 31 October 2015
Revised date: 13 January 2016
Accepted date: 26 February 2016

Cite this article as: Brendon Stubbs, Davy Vancampfort, Nicola Veronese, Marco Solmi, Fiona Gaughran, Peter Manu, Simon Rosenbaum, Marc De Hert and Michele Fornaro, The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis, *Journal of Affective Disorders* <http://dx.doi.org/10.1016/j.jad.2016.02.060>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

From: Brendon Stubbs [mailto:brendonstubbs@hotmail.com]

Sent: 06 March 2016 22:56

To: N, Vijay (ELS-CON)

Subject: Re: File problems for your article [JAD_8078] in Journal of Affective Disorders

Dear colleague

Please see below for the affiliations.

When will this paper be available online?

Thank you

Brendon Stubbs^{1,2}, Davy Vancampfort^{3,4}, Nicola Veronese⁵, Marco Solmi^{6,7}, Fiona Gaughran⁸, Peter Manu⁹, Simon Rosenbaum^{10,11}, Marc De Hert¹², Michele Fornaro¹³

1. Health Service and Population Research Department, Institute of Psychiatry, King's College London, De Crespigny Park, London, Box SE5 8AF, United Kingdom;
2. Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom.
3. KU Leuven Department of Rehabilitation Sciences, Tervuursevest 101, B-3001 Leuven, Belgium
4. University Psychiatric Centre KU Leuven, Kortenberg, KU Leuven Departement of Neurosciences, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium
5. Department of Medicine, DIMED, University of Padua, Via Giustiniani, 2, 35128 Padova, Italy.
6. Department of Neurosciences, University of Padua, Via Giustiniani, 5, 35128 Padova, Italy.
7. Local Health Unit ULSS 17, Mental Health Department, Monselice (Padova), Italy
8. National Psychosis Service, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK
9. Zucker Hillside Hospital, North Shore - LIJ Health System, 75-59 263rd Street, Glen Oaks, NY, 11004, USA
10. Musculoskeletal Division, The George Institute for Global Health and School of Public Health, University of Sydney, Sydney, Australia
11. School of Psychiatry, University of New South Wales, Sydney, Australia

12. KU Leuven - University of Leuven, Department of Neurosciences, B-3000 Leuven, Belgium; University Psychiatric Centre, Z.org KU Leuven, Belgium

13. New York Psychiatric Institute, Columbia University, NYC, USA

Brendon Stubbs

Post-doctoral research physiotherapist, Institute of Psychiatry, Psychology and Neuroscience, Kings College London.

Head of Physiotherapy, South London and Maudsley NHS Foundation trust.

Email: brendon.stubbs@kcl.ac.uk

Telephone: 0203 228 3877

Mobile: 07920 831 431

On 5 Mar 2016, at 03:56, <V.N@elsevier.com> <V.N@elsevier.com> wrote:

Our reference: JAD 8078

Article reference: JAD_2015_1336

Article title: The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis

To be published in: Journal of Affective Disorders

Dear Dr. Stubbs,

We have received your accepted manuscript and would like to begin the typesetting process.

Unfortunately we have encountered a problem with the electronic files you provided and cannot process your article further until the following issues are resolved:

* The following figure(s)/table(s) is/are missing: I have been contacted by the typesetter regarding the files for your article. The typesetter has found the following problem with the files provided:

"Affiliations 11,12 and 13 are given in affiliations list but not linked with the authors name in author group in title page."

Please e-mail me citations for the affiliations 11, 12 and 13 as soon as possible so that we may proceed with the publication of your article.

Thank you in advance for your assistance and prompt attention to this matter.

Further information on acceptable file formats can be found at
<http://www.elsevier.com/guidepublication>.

Please quote the reference for your article, JAD 8078, in all of your messages to us.

Thank you for your help in resolving this issue; I look forward to hearing from you soon.

Kind regards,

Mr. N. Vijay
 Data Administrator
 Elsevier
 E-Mail: V.N@elsevier.com

 HAVE QUESTIONS OR NEED ASSISTANCE?

For further assistance, please visit our Customer Support site, where you can search for solutions on a range of topics and find answers to frequently asked questions. You can also talk to our customer support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

Get started here: <http://service.elsevier.com/app/home/supporthub/publishing>

 Copyright © 2015 Elsevier B.V. | Privacy Policy <http://www.elsevier.com/privacypolicy>
 Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084

The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis

Submission to Journal of Affective Disorder

Brendon Stubbs^{1,2}, Davy Vancampfort^{3,4}, Nicola Veronese⁵, Marco Solmi^{6,7}, Fiona Gaughran⁵

Peter Manu⁶, Simon Rosenbaum^{7,8}, Marc De Hert⁹, Michele Fornaro¹⁰

1. Health Service and Population Research Department, Institute of Psychiatry, King's College London, De Crespigny Park, London, Box SE5 8AF, United Kingdom;

2. Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom.
3. KU Leuven Department of Rehabilitation Sciences, Tervuursevest 101, B-3001 Leuven, Belgium
4. University Psychiatric Centre KU Leuven, Kortenberg, KU Leuven Departement of Neurosciences, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium
5. Department of Medicine, DIMED, University of Padua, Via Giustiani, 2, 35128 Padova, Italy.
6. Department of Neurosciences, University of Padua, Via Giustiniani, 5, 35128 Padova, Italy.
7. Local Health Unit ULSS 17, Mental Health Department, Monselice (Padova), Italy
8. National Psychosis Service, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK
9. Zucker Hillside Hospital, North Shore - LIJ Health System, 75-59 263rd Street, Glen Oaks, NY, 11004, USA
10. Musculoskeletal Division, The George Institute for Global Health and School of Public Health, University of Sydney, Sydney, Australia
11. School of Psychiatry, University of New South Wales, Sydney, Australia
12. KU Leuven - University of Leuven, Department of Neurosciences, B-3000 Leuven, Belgium; University Psychiatric Centre, Z.org KU Leuven, Belgium
13. New York Psychiatric Institute, Columbia University, NYC, USA

Abstract*Background*

Obstructive sleep apnea (OSA) is a health hazard since it is associated with neurocognitive dysfunction and cardio-metabolic diseases. The prevalence of OSA among people with serious mental illness (SMI) is unclear.

Method

We searched major electronic databases from inception till 06/2015. Articles were included that reported the prevalence of OSA determined by polysomnography (PSG) or an apnea-hypopnea index (AHI) >5 events/hr, in people with major depressive disorder (MDD), bipolar disorder (BD) or schizophrenia. A random effects meta-analysis calculating the pooled prevalence of OSA and meta-regression of potential moderators were performed.

Results

Twelve articles were included representing 570,121 participants with SMI (mean age=38.3 years (SD=7.5)), 45.8% male (range=32-80.4) and mean body mass index (BMI) 25.9 (SD=3.7). The prevalence of OSA in SMI in clinical studies was 25.7% (95% CI 13.9 to 42.4%, n=1,535). Higher frequencies of OSA were seen in MDD (36.3%, 19.4 - 57.4%, n=525) than in BD (24.5%, 95% CI 10.6 - 47.1, n=681) and schizophrenia (15.4%, 95% CI 5.3 - 37.1%, n=329). The prevalence of OSA in 568,586 people with SMI from population cohort studies was 10.7% (95% CI 2.4 - 37.0%) and 19.8% (95% CI 2.5 - 70.0%) in 358,853 people with MDD. Increasing age ($\beta=0.063$, 95% CI 0.0005 - 0.126, $p=0.04$, $N=10$) and BMI predicted increased prevalence of OSA ($\beta=0.1642$, 95% CI 0.004 - 0.3701, $p=0.04$, $N=9$).

Conclusion

People with SMI (particularly MDD) have a high prevalence of OSA. Screening for and interventions to manage OSA in SMI including those focused on reducing BMI are warranted.

Key words: obstructive sleep apnea, sleep, serious mental illness, major depressive disorder, bipolar disorder, schizophrenia

Accepted manuscript

Introduction

Obstructive sleep apnea (OSA) is an important cause for a number of medical comorbidities and premature mortality (Punjabi, 2008). OSA is characterised by recurrent episodes of pharyngeal obstructions during sleep resulting in a reduction in airflow which can cause derangements in gaseous exchange and disturbed sleep (Punjabi, 2008; Sharafkhaneh, Giray, Richardson, Young, & Hirshkowitz, 2005; Sharafkhaneh, Richardson, & Hirshkowitz, 2004). As a result OSA is associated with a range of adverse outcomes including daytime sleepiness (Johns, 1993) and cognitive dysfunction (Olaithe & Bucks, 2013). It may result in the development of hypertension (Peppard, Young, Palta, Dempsey, & Skatrud, 2000), cardiovascular disease (Peker, Carlson, & Hedner, 2006) and abnormalities in glucose metabolism (Punjabi & Polotsky, 2005). Moreover, OSA often has a deleterious impact on quality of life (Punjabi, 2008) and is associated with symptoms of anxiety and depression (Rezaeitalab, Moharrari, Saberi, Asadpour, & Rezaeetalab, 2014).

People with serious mental illness (SMI) (defined as major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia spectrum disorders) have significantly poorer physical health than the general population and are at increased risk of comorbidities (Smith, Langan, McLean, Guthrie, & Mercer, 2013a; Smith et al., 2013b; Stubbs et al., 2014). Of particular concern is the high prevalence of obesity (Mitchell, Vancampfort, De Herdt, Yu, & De Hert, 2013a; Mitchell et al., 2013b) diabetes (Stubbs, Vancampfort, De Hert, & Alex, 2015 (in press); Vancampfort, Mitchell, De Hert, & Stubbs, 2015 (in press)) and metabolic syndrome (Mitchell et al., 2013a; Mitchell et al., 2013b).

More recently, research has considered the relationship between SMI and respiratory diseases. For instance, in a population cohort study (Partti et al., 2015) demonstrated that schizophrenia is associated with increased odds of having chronic obstructive pulmonary disease (COPD, OR=4.2) and chronic bronchitis (OR=3.8). Furthermore, reduced lung

function (Vancampfort et al., 2014) can negatively influence participation in daily life among patients with schizophrenia. One of the most prevalent respiratory disorder is OSA. Key risk factors for OSA include obesity, craniofacial abnormalities (Sutherland, Lee, & Cistulli, 2012), allergic rhinitis (Farabollini, Braschi, & Bonifazi, 2009) and cardiovascular disease (Young, Skatrud, & Peppard, 2004). In addition, lifestyle factors such as smoking and alcohol misuse increase an individual's risk of OSA (Punjabi, 2008). These comorbidities and lifestyle factors are particularly prevalent among people with SMI and therefore it is reasonable to assume that this group may be at increased risk of OSA. As such, the identification and management of OSA in people with SMI may be important in preventing or attenuating cardio-metabolic comorbidities associated with SMI (Punjabi, 2008; Young et al., 2004). The relationship between OSA and cardiovascular disease, stroke, hypertension and altered glucose metabolism is complex and appears to be bidirectional (Punjabi, 2008; Young et al., 2004). Nevertheless, understanding the prevalence of OSA in people with SMI is important.

Previously, a number of narrative systematic reviews have considered the prevalence of OSA in schizophrenia (Kalucy, Grunstein, Lambert, & Glozier, 2013), and SMI more generally (Gupta & Simpson, 2015). Whilst not focussing on OSA, another review (Plante & Winkelman, 2008) established the critical relationship between sleep disturbances generally and bipolar disorder. Although these reviews have advanced the field, a number of limitations persist. First, none have attempted to conduct a meta-analysis and the prevalence of OSA was limited to considering individual studies as single entities or calculating arithmetic means or medians of the prevalence of OSA. Meta-analyses enable the pooling of data across studies in order to provide a more accurate effect size than when individual studies are considered separately (Ioannidis, 2009). The recent reviews have also considered differing inclusion criteria when reviewing the literature on OSA. For instance, (Gupta &

Simpson, 2015) only considered studies measuring OSA confirmed by polysomnography (PSG) the gold standard recognised by the International Classification of Sleep Disorders 2nd edition (ICSD-2) (Medicine, 2005) criteria. However, (Kalucy et al., 2013) considered ‘sleep disordered breathing’ including studies that report OSA from screening questionnaires.

We aimed to conduct a meta-analysis investigating the prevalence of OSA in SMI and investigate diagnostic subgroup differences among people with MDD, BD and schizophrenia when determined according to standardised OSA measures. Where possible, we anticipated conducting a comparative meta-analysis comparing the risk of OSA in people with SMI versus the general population. Moreover, we sought to investigate differences reported in clinical and population cohort studies and conduct meta-regression analyses on potential moderator variables (if reported in at least 4 studies).

Method

This systematic review was conducted in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines (Stroup et al., 2000) and reported in accordance with the PRISMA statement (Moher, Liberati, Tetzlaff, & Altman, 2009) following a predetermined but unpublished protocol.

Inclusion and exclusion criteria

We included observational (clinical or population cohort) studies (prospective, retrospective or cross-sectional) that: (a) included people with a diagnosis of MDD, BD or schizophrenia spectrum disorders according to a structured clinical assessment and/ or meeting standardised diagnostic criteria (e.g. DSM-IV (Association, 2000) or ICD-10 (organisation, 1993)) (b) assessed for OSA in line with the international classification of sleep disorders, 2nd edition diagnostic and coding manual (Medicine, 2005). This includes PSG (single or split-night) or OSA with apnea-hypopnea index (AHI, the number of episodes of apnea or hypopnea per hour during sleep) ≥ 5 events/h or the respiratory disturbance index (RDI) equivalent (Medicine, 2005). We excluded studies that measured OSA with screening instruments alone or studies that identified those with SMI using a screening tool alone. When we encountered studies reporting data from the same sample at different time points, we used the most recent data and/or the largest data set. If necessary, we planned to contact study authors to confirm eligibility and/ or to acquire data, although this was not needed.

Information sources and searches

Two independent reviewers (B.S. and M.F.) searched Academic Search Premier, MEDLINE, Psychology and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and Pubmed from inception until June 2015. We used the key words 'bipolar disorder' or

‘bipolar*’ or ‘affective disorders’ or ‘schizophrenia’ or ‘psychosis’ or ‘depression’ or major depression AND ‘sleep’ or ‘sleep apnea’ or ‘obstructive sleep apnea’. In addition, the reference lists of all eligible articles and recent narrative systematic reviews on OSA and sleep disorders in people with SMI were reviewed (Gupta & Simpson, 2015; Kalucy et al., 2013). Only articles written in Italian or English were included.

Study Selection

After the removal of duplicates, two independent reviewers screened the titles and abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of full text articles was developed through consensus. The two reviewers then considered the full texts of these articles and the final list of included articles was reached through consensus.

Data Extraction

Two authors (B.S. and M.F.) independently extracted data and recorded this in a predetermined database. The data collected from each article included: study design, geographical location, details of SMI participants (mean age, percentage of males, diagnosis method, body mass index (BMI), details of medications and chronicity of illness) and details regarding diagnosis. In addition, we sought to extract data on the classification of OSA and number diagnosed with OSA.

Methodological quality appraisal

We used the Newcastle Ottawa Scale (NOS; (Wells, Shea., O'Connell, & Peterson)) to assess the methodological quality of all included articles. We included studies without a control group due to the paucity of data and such studies were treated as cross sectional case controlled studies for the purposes of methodological assessment. Naturally it was anticipated these studies to have a low methodological quality rating. The NOS assesses the

quality of non-randomised trials and its validity and reliability has been established (Wells et al.) and such criterion is particularly essential when critically appraising studies without a control group. The NOS focuses on three main methodological features: 1) the selection of the groups, 2) the comparability of the groups and 3) the ascertainment of the outcome of interest. The maximum score that any study can achieve on the NOS is 9 points. Studies that score 5 or more are normally considered of satisfactory methodological quality. Due to the paucity of literature we included studies with a score less than this (due to the absence of a control group). The methodological assessment was independently completed by two authors and consensus was reached through discussion.

Meta- analysis

We pooled individual study data using the DerSimonian-Laird proportion method (DerSimonian R. & N., 1988) which calculates pooled prevalence using inverse-variance weighted random effects meta-analysis with StatsDirect® and Comprehensive Meta-Analysis® software (version 3). Due to anticipated heterogeneity, a random effects meta-analysis was employed. If there were 3 or more studies with relevant data, we planned to calculate subgroup analyses of the prevalence of OSA according to SMI diagnostic classification. We also anticipated completing separate subgroup analyses investigating the pooled prevalence of OSA in clinical and population cohort studies and conducted a comparative relative risk (RR) meta-analysis to establish if OSA is more common in people with SMI versus controls. We assessed publication bias with the visual inspection of a funnel plot (Higgins JPT & S) and the Begg (Begg & Mazumdar, 1994) and Egger (Egger, Davey Smith, Schneider, & Minder, 1997) tests. Finally, we conducted several meta-regression analyses (if $N \geq 4$) to investigate potential moderators (age, percentage males and BMI) with Comprehensive Meta-Analysis® (version 3). Despite a lack of consensus on the number of

studies required for meta-regression, we chose to only conduct meta regression where data was available from 4 or more studies based on recent recommendations (Fu et al., 2011). We anticipated conducting meta regression analyses to investigate the influence of mean age, methodological quality, percentage of males, psychopathology/ depressive symptoms, the percentage taking psychotropic and antipsychotic medication.

Accepted manuscript

Results

Search results and study selection

The initial search identified 2,215 publications. After removal of duplicates, 221 abstracts and titles were screened (Figure 1). At the full text review stage, 62 articles were considered and 50 articles were excluded with reasons which are listed in figure 1. Thus, 12 articles met the eligibility criteria and were included in the review (Ancoli-Israel et al., 1999; Carney et al., 2006; Deldin, Phillips, & Thomas, 2006; Hattori, 2009; Hrubos-Strøm et al., 2012; Kelly, Douglas, Denmark, Brasuell, & Lieberman, 2013; Levine et al., 2001; Mysliwiec et al., 2013; Ong, Gress, San Pedro-Salcedo, & Manber, 2009; Sharafkhaneh et al., 2005; Soreca, Levenson, Lotz, Frank, & Kupfer, 2012; Winkelman, 2001). Details regarding the search results including reasons for exclusion of articles are summarised in figure 1.

Figure 1 here

Study and participant characteristics

Across the 12 unique included studies 570,121 unique participants with SMI were included. One study included a substantial percentage of the participants included in our meta-analysis (about 99.7% of the whole sample). The mean age across the studies of participants was 38.3 years (SD=7.5) and 45.8% of the included participants were male (range=32-80.4%). The mean BMI across 10 studies with complete data was 25.9 (SD=3.7) (overweight). Across the 12 studies, 9 considered OSA in MDD (n=359,378)(Carney et al., 2006; Deldin et al., 2006; Hattori, 2009; Hrubos-Strøm et al., 2012; Levine et al., 2001; Mysliwiec et al., 2013; Ong et al., 2009; Sharafkhaneh et al., 2005; Winkelman, 2001). Six studies provided data on 72,043 people with BD (Hattori, 2009; Kelly et al., 2013; Levine et al., 2001; Sharafkhaneh et al., 2005; Soreca et al., 2012; Winkelman, 2001) and 4 studies provided data on 138,700 people with schizophrenia spectrum disorders (Ancoli-Israel et al., 1999; Levine et al., 2001; Sharafkhaneh et al., 2005; Winkelman, 2001). Only two of the included studies were

population cohort designs (Hrubos-Strøm et al., 2012; Sharafkhaneh et al., 2005) and the remainder included clinical samples. The average NOS was 4.25 (range 4-5). Full details of the included studies according to SMI diagnosis are summarised in table 1.

Table 1 here

Meta-analysis of the prevalence of OSA in clinical studies

Prevalence of OSA among people with SMI

Data were pooled from 1,535 unique participants with SMI resulting in a pooled prevalence of OSA of 25.7% (95% CI 13.9 to 42.4, $Q=156$ (df=13) $p<0.01$) (figure 2). The Begg (-0.9, $p=0.59$) and Egger tests (-0.45, $p=0.79$) did not demonstrate any evidence of publication bias in the overall pooled analyses.

Prevalence of OSA among different diagnostic subgroups

Data was pooled from 6 clinical studies from 522 people with MDD to establish a pooled prevalence of OSA of 36.3% (95% CI 19.4 to 57.4, $Q=82.83$, (df=6) $p<0.01$). The pooled prevalence of OSA among 681 people with BD was 24.5% (95% CI 10.6 to 47.1, $Q=26.55$ (df=4) $p<0.01$). The prevalence of OSA among 329 people with schizophrenia was 15.4% (95% CI 5.3 to 37.1, $Q=46$ (df=3), $p<0.01$). The prevalence of OSA in each diagnostic subgroup is presented in figure 2.

Figure 2 here

Sensitivity analyses

Two studies (Carney et al., 2006, Ong et al., 2009) focussing on people with MDD were identified as being potentially biased due to the nature of included participants. Therefore, these were removed in a sensitivity analysis and the pooled prevalence of OSA among 378 people with MDD was recalculated at 25.2% (95% CI 10.2 to 50.2, $Q=58$, $p<0.01$). The

overall pooled prevalence of OSA in SMI established the pooled prevalence of OSA was 25.5% (95% CI 16.6 to 37.6, $Q=199$, $p<0.01$, $n=1,314$).

Meta regression of pooled prevalence of OSA in SMI

Meta regression analysis using data from 10 studies established that a higher mean age predicted an increased prevalence of OSA in the SMI participants ($\beta=0.063$, 95% CI 0.0005 to 0.126, $z=1.97$, $p=0.04$, $R^2=0.34$). Meta-regression with data from 9 studies established that higher BMI predicted increased prevalence of OSA ($\beta=0.1642$, 95% CI 0.004 to 0.3701, $z=1.56$, $p=0.04$, $R^2=0.23$). No relationship was found with the percentage of males in the studies ($p>0.05$, $N=9$) or methodological quality according to the NOS ($p>0.05$, $N=10$).

Prevalence of OSA in population cohort studies

Data were pooled from 4 samples utilising two studies including 359,378 people with MDD, 72,043 with BD and 138,700 people with schizophrenia. As reported in Figure 3, the pooled prevalence of OSA among a total of 568,586 people with SMI was 10.7% (95% CI 2.4 to 37.0, 1368.3 (df=3), $p<0.01$). The pooled prevalence of OSA in MDD, calculated from pooled data from two unique studies was 19.8% (95% CI 2.5 to 70.0).

Figure 3 here

Discussion

General findings

Results our meta-analysis demonstrates in clinical studies that approximately a quarter of people with SMI meet the criteria for OSA. People with MDD appear to have a higher prevalence of OSA compared to people with BD or schizophrenia. However, after the removal of two potentially biased studies the prevalence of OSA in MDD appears similar to BD. When we considered population cohort data only, the pooled prevalence of OSA was lower at 10.7%, although pooled data from the two MDD cohorts suggest that OSA is higher in this population (19.8%). We found that both increasing age and increased BMI predict an elevated prevalence of OSA among people with SMI.

The increased prevalence of OSA in MDD compared to other diagnostic subgroups is of interest and warrants further investigation. It has been previously suggested that sleep fragmentation associated with hypoxaemia and altered serotonergic neurotransmission, as well as common shared risk factors for both MDD and OSA may account for an increased prevalence of OSA in people with MDD (Schroder & O'Hara 2005). Among pathways linking OSA and MDD, low serotonin levels seem to play an important role since serotonin has been involved in both the development of depression (Muñoz, Mayoralas, Barbé, Pericás, & Agusti, 2000) and might also influence upper airway dilator motor neurons particularly through the hypoglossal nucleus (Canessa et al., 2011). In people with MDD, the early identification and treatment of OSA seems to correspond to a better improvement of depressive symptoms (Edwards et al., 2015). OSA and MDD are risk factors for the development of obesity (El-Ad & Lavie, 2005), cardiovascular disease (Vozoris, 2012), and metabolic syndrome (Lett et al., 2004), while there is also an increased risk in both disorders of excessive alcohol consumption (Harris, Glozier, Ratnavadivel, & Grunstein, 2009). In

addition, given that in the general population OSA is independently associated with metabolic syndrome (Coughlin, Mawdsley, Mugarza, Calverley, & Wilding, 2004), cardiovascular disease (Peker et al., 2006) and abnormalities in glucose metabolism (Punjabi, 2008), the identification and management of OSA may prove also a valuable means to prevent cardiovascular disease in people with MDD.

Obtaining the precise prevalence of OSA in the general population is challenging and many cases within the general population are under-recognised (Ravesloot, van Maanen, Hilgevoord, van Wagenveld, & de Vries, 2012), with previous research suggesting 1-2% and 2-4% of women and men are affected (Gibson, 2005). Others have suggested a higher prevalence in studies conducted in clinical settings with (Young et al., 1993) establishing a prevalence of 24% and 9% in males and females with an AHI>5. Unfortunately, there were insufficient data to enable a comparative meta-analysis to directly compare the prevalence of OSA in people with SMI versus general population controls. Thus, it remains unclear if people with SMI are at increased risk of OSA compared to people in the general population. However, the pooled prevalence of OSA in MDD was 36.3% which is higher than previous estimates in the general population (Young et al., 1993). Studies that have previously investigated sleep disordered breathing in MDD defined according to structured clinical assessment have reported greatly increased rates of OSA, with odds ratios of over 5, thus also supporting our results that people with MDD are particularly at increased risk (Ohayon, 2003). Moreover, a previous narrative systematic review tabulated the median prevalence of OSA in MDD (Gupta & Simpson, 2015) and reported this as 48.1%. Thus, utilising meta-analysis we were able to establish that the prevalence of OSA in MDD in clinical settings appears to be less than that reported previously (Gupta & Simpson, 2015). It was also possible to pool data from 358,853 people with MDD and establish the prevalence of OSA in

population cohort studies is almost one in 5 (19.8%). Given the likely bias attributed to the studies conducted in clinical settings, the prevalence in population studies may be a truer reflection of the actual prevalence of OSA.

The pooled prevalence of OSA in BD in clinical settings was 24.5% and is comparable to clinical studies in the general population (Young et al., 1993), yet higher than the arithmetic median reported in a previous narrative review (19.8%) (Gupta & Simpson, 2015). Our pooled analysis of 4 clinical studies in schizophrenia established that 15.4% are affected by OSA, lower than reported in the general population. A previous narrative review suggested people with schizophrenia have a particularly high prevalence of OSA (Kalucy et al., 2013). Our current findings should however be interpreted with caution given the limitations in the available data. Moreover, only one representative study (Sharafkhaneh et al., 2005) adopted a population cohort study approach which reported 4.5% and 6.9% of people with schizophrenia and BD have OSA respectively. Therefore, it is important that future representative research is conducted to attempt to build on the results of our review and establish the true prevalence of OSA in the diagnostic SMI groups.

The finding that increasing BMI is a significant predictor of increased prevalence of OSA is of interest. Many people with SMI experience increased levels of BMI and in particular central adiposity (De Hert et al., 2011; Gardner-Sood P, Lally J, & al, 2015) which is known to increase the risk of OSA in the general population (El-Ad & Lavie, 2005). Reasons for high BMI values in people with SMI could be the high prevalence of sedentary lifestyle (Stubbs et al., 2015) and the use of antipsychotic medications that could contribute to obesity in this population. Given this finding, there is further need to develop preventive lifestyle interventions to reduce weight gain in people with mental illness. Future work is needed to

investigate the impact of medication on OSA risk in people with SMI. Moreover, other sedative medications commonly prescribed to people with SMI such as benzodiazepines may also increase the risk of OSA (Gupta & Simpson, 2015). Research in the general population has established that men are at particularly increased risk of OSA (Gibson, 2005; Young et al., 1993). However, we were unable to elucidate any gender effects in our meta-regression analyses.

There are a number of reasons why identifying and managing OSA is clinically important among people with SMI. First, OSA can result in neurocognitive and mood deterioration among people with mental health problems through intermittent hypoxia and disrupted sleep (Bucks, Olaithe, & Eastwood, 2013; Gupta & Simpson, 2015). Clearly, this is an unwanted potential consequence among people who already experience compromised cognition and mood instability (Gupta & Simpson, 2015). Second, if left untreated there are considerable concerns that OSA may increase the risk of cardiovascular disease, impair glucose regulation and increase the risk of metabolic syndrome. Previous work from our group has extensively documented that people with SMI are at risk of metabolic syndrome (Gardner-Sood P et al., 2015 (in press); Mitchell et al., 2013a; Mitchell et al., 2013b; Vancampfort et al., 2013) and diabetes (Stubbs et al., 2015 (in press); Vancampfort et al., 2015 (in press)). Emerging evidence has demonstrated a number of mechanisms which underlie the relationship between OSA and metabolic dysregulation including sympathetic activation, oxidative stress and related inflammation (JC & SM, 2012). Given that cardiovascular disease is a major cause of premature mortality in people with SMI (Walker, McGee, & Druss, 2015), the increased prevalence of OSA is a concern. OSA has been identified as a cause of sudden death in the community (Gami et al., 2013) and among psychiatric patients (Manu, Kane, & Correll, 2011). The magnitude of the risk is predicted by the presence and severity of nocturnal

hypoxemia (Gami et al., 2013), an issue of particular concern in psychiatric patients who refuse continuous positive airway pressure (CPAP) or Bilevel Positive Airway Pressure treatment and/or are treated with benzodiazepines or other CNS-depressant psychotropic drugs (Seda, Tsai, & Lee-Chiong, 2014). A previous Cochrane review (Giles et al., 2006) suggests that CPAP may be effective in managing OSA, however there are no rigorous trials investigating this in people with SMI (Kalucy et al., 2013).

Limitations

Although this meta-analysis provides novel findings, there are a number of limitations that must be considered, particularly in light of the data available from the included studies. First, there was some heterogeneity encountered within the study design and participants. We attempted to negate this by conducting sub-group analyses and meta-regressions. Second, the pooled analyses on clinical studies of OSA may not be representative of the wider SMI populations. The meta-analyses results drawn from population cohort studies were sparse but may be a more accurate reflection of the prevalence of OSA. However, these should be interpreted in light of the caveats mentioned above (i.e. clinical setting and overshadowing of co-morbid medical conditions in patients with SMI), indicating the frequencies reported may be underestimates. In this sense, one study (Sharafkhaneh et al., 2005), which accounted for the overwhelming majority of participants in our meta-analysis reported a lower prevalence of OSA than the other studies included in our analyses. Third, there was inadequate comparative data of healthy controls to conduct a meta-analysis to understand if people with SMI are at increased risk of OSA. Representative research is required to understand this further. Fourth, there was inadequate data on important moderators such as antipsychotic medication which may influence OSA. Future research is

clearly required to better understand these relationships. Finally, our meta regression considered the SMI group as a whole since there was insufficient data to consider each diagnostic group separately. However, this might have resulted in potentially spurious results, which should be clarified in larger representative studies within each diagnostic group. Nevertheless, allowing for these caveats our meta-analysis provides the most systematic quantitative analysis of the prevalence and predictors of the OSA in people with SMI.

Conclusion

Our meta-analysis established that 25.7% of people with SMI have OSA. Higher frequencies were found in MDD (36.3%) compared to BD (24.5%) and schizophrenia (15.4%) although for BD and schizophrenia our findings are unclear due to the small number of the studies included for these conditions. Clearly people with SMI are at risk of OSA and this may negatively impact a range of health outcomes and therefore warrants closer attention in clinical practice. Moreover, future representative research is required to better understand the incidence and prevalence of OSA across all people with SMI with a view to developing effective interventions.

Conflict of Interest

BS, SR, PM, DV and MF declare no conflict of interest.

FG has received honoraria for advisory work and lectures from Roche, BMS, Lundbeck, and Sunovion and has a family member with professional links to Lilly and GSK.

MDH has

Funding

None.

Accepted manuscript

References

- Ancoli-Israel, S., Martin, J., Jones, D. W., Caligiuri, M., Patterson, T., Harris, M. J., & Jeste, D. V. 1999. Sleep-disordered breathing and periodic limb movements in sleep in older patients with schizophrenia. *Biological Psychiatry*, 45(11): 1426-1432.
- American Academy of Sleep Medicine,. 2005. The international classification of sleep disorders, 2nd ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine.
- American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders – DSM-IV-TR. 4th edition: American Psychiatric Association.
- Begg, C. B., & Mazumdar, M. 1994. Operating characteristics of a rank correlation test for publication bias. *Biometrics*, 50(4): 1088-1101.
- Bucks, R. S., Olaithe, M., & Eastwood, P. 2013. Neurocognitive function in obstructive sleep apnoea: A meta-review. *Respirology*, 18(1): 61-70.
- Carney, R. M., Howells, W. B., Freedland, K. E., Duntley, S. P., Stein, P. K., Rich, M. W., & Miller, G. E. 2006. Depression and obstructive sleep apnea in patients with coronary heart disease. *Psychosomatic Medicine*, 68(3): 443-448.
- Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Calverley, P. M. A., & Wilding, J. P. H. 2004. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *European Heart Journal*, 25(9): 735-741.
- De Hert, M., Correll, C. U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Detraux, J., Gautam, S., Möller, H.-J., Ndeti, D. M., Newcomer, J. W., Uwakwe, R., & Leucht, S. 2011. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry: Official Journal Of The World Psychiatric Association (WPA)*, 10(1): 52-77.

- Deldin, P. J., Phillips, L. K., & Thomas, R. J. 2006. A preliminary study of sleep-disordered breathing in major depressive disorder. *Sleep Medicine*, 7(2): 131-139.
- DerSimonian R., & N., L. 1988. Meta-Analysis in Clinical Trials. *Controlled Clinical Trials*, 7: 177-188.
- Egger, M., Davey Smith, G., Schneider, M., & Minder, C. 1997. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)*, 315(7109): 629-634.
- El-Ad, B., & Lavie, P. 2005. Effect of sleep apnea on cognition and mood. *International Review of Psychiatry*, 17(4): 277-282.
- Farabollini, B., Braschi, M. C., & Bonifazi, F. 2009. Allergic rhinitis and associated pathologies: the rationale for steroid options. *European Annals Of Allergy And Clinical Immunology*, 41(3): 67-79.
- Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., Santaguida, P., Lau, J., & Trikalinos, T. A. 2011. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. *Journal Of Clinical Epidemiology*, 64(11): 1187-1197.
- Gami, A. S., Olson, E. J., Shen, W. K., Wright, R. S., Ballman, K. V., Hodge, D. O., Herges, R. M., Howard, D. E., & Somers, V. K. 2013. Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death: A Longitudinal Study of 10,701 Adults. *Journal of the American College of Cardiology (JACC)*, 62(7): 610-616.
- Gardner-Sood P, Lally J , et al. 2015 (in press). Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT RCT study. *Psychological Medicine*.
- Gibson, G. J. 2005. Obstructive sleep apnoea syndrome: underestimated and undertreated. *British Medical Bulletin*, 72: 49-65.

Giles, T. L., Lasserson, T. J., Smith, B. H., White, J., Wright, J., & Cates, C. J. 2006. Continuous positive airways pressure for obstructive sleep apnoea in adults. The Cochrane Database Of Systematic Reviews(3): CD001106.

Gupta, M. A., & Simpson, F. C. 2015. Obstructive sleep apnea and psychiatric disorders: a systematic review. Journal Of Clinical Sleep Medicine: JCSM: Official Publication Of The American Academy Of Sleep Medicine, 11(2): 165-175.

Harris, M., Glozier, N., Ratnavadivel, R., & Grunstein, R. R. 2009. Obstructive sleep apnea and depression. Sleep Medicine Reviews, 13(6): 437-444.

Hattori, M. Kitajima T, Mekata T, Kanamori A, Imamura M, Sakakibara H, Kayukawa Y, Okada T, Iwata N.. 2009. Risk factors for obstructive sleep apnea syndrome screening in mood disorder patients. Psychiatry & Clinical Neurosciences, 63(3): 385-391.

Higgins JPT, & Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Hrubos-Strøm, H., Einvik, G., Nordhus, I. H., Randby, A., Pallesen, S., Moum, T., Omland, T., & Dammen, T. 2012. Sleep apnoea, anxiety, depression and somatoform pain: a community-based high-risk sample. The European Respiratory Journal, 40(2): 400-407.

Ioannidis, J. P. 2009. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ: Canadian Medical Association Journal, 181(8): 488-493.

Lam JC, L., & Ip, SM,. 2012. Obstructive sleep apnoea Metabolic consequences: pathophysiology and clinical implications. Medicine, April 2014, Pages 78-92.

Johns, M. W. 1993. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest, 103(1): 30-36.

- Kalucy, M. J., Grunstein, R., Lambert, T., & Glozier, N. 2013. Obstructive sleep apnoea and schizophrenia--a research agenda. *Sleep Medicine Reviews*, 17(5): 357-365.
- Kelly, T., Douglas, L., Denmark, L., Brasuell, G., & Lieberman, D. Z. 2013. The high prevalence of obstructive sleep apnea among patients with bipolar disorders. *Journal of Affective Disorders*, 151(1): 54-58.
- Lett, H. S., Blumenthal, J. A., Babyak, M. A., Sherwood, A., Strauman, T., Robins, C., & Newman, M. F. 2004. Depression as a Risk Factor for Coronary Artery Disease: Evidence, Mechanisms, and Treatment. *Psychosomatic Medicine*, 66(3): 305-315.
- Levine, J., Chengappa, K. N., Patel, A., Vagnucci, A., John, V., Brar, J. S., Chalasani, L., Parepally, H., & Ganguli, R. 2001. Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. *Journal Of Psychiatric Practice*, 7(6): 432-439.
- Manu, P., Kane, J. M., & Correll, C. U. 2011. Sudden deaths in psychiatric patients. *The Journal Of Clinical Psychiatry*, 72(7): 936-941.
- Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. 2013a. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. *Schizophrenia Bulletin*, 39(2): 295-305.
- Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. 2013b. Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis. *Schizophrenia Bulletin*, 39(2): 306-318.
- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Clinical Trials*, 6(7): 1-6.

- Mysliwiec, V., McGraw, L., Pierce, R., Smith, P., Trapp, B., & Roth, B. J. 2013. Sleep disorders and associated medical comorbidities in active duty military personnel. *Sleep*, 36(2): 167-174.
- Ohayon, M. M. 2003. The Effects of Breathing-Related Sleep Disorders on Mood Disturbances in the General Population. *Journal of Clinical Psychiatry*, 64(10): 1195-1200.
- Olaithe, M., & Bucks, R. S. 2013. Executive Dysfunction in OSA Before and After Treatment: A Meta-Analysis. *Sleep*, 36(9): 1297-1305.
- Ong, J. C., Gress, J. L., San Pedro-Salcedo, M. G., & Manber, R. 2009. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. *Journal of Psychosomatic Research*, 67(2): 135-141.
- World Health Organisation, 1993. The ICD-10 Classification of Mental and Behavioural Disorders – Diagnostic Criteria for Research.
- Partti, K., Vasankari, T., Kanervisto, M., Perälä, J., Saarni, S. I., Jousilahti, P., Lönnqvist, J., & Suvisaari, J. 2015. Lung function and respiratory diseases in people with psychosis: population-based study. *The British Journal Of Psychiatry: The Journal Of Mental Science*.
- Peker, Y., Carlson, J., & Hedner, J. 2006. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. *The European Respiratory Journal*, 28(3): 596-602.
- Peppard, P. E., Young, T., Palta, M., Dempsey, J., & Skatrud, J. 2000. Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA*, 284(23): 3015-3021.
- Plante, D. T., & Winkelman, J. W. 2008. Sleep disturbance in bipolar disorder: Therapeutic implications. *The American Journal of Psychiatry*, 165(7): 830-843.
- Punjabi, N. M. 2008. The epidemiology of adult obstructive sleep apnea. *Proceedings of the American Thoracic Society*, 5(2): 136-143.

Punjabi, N. M., & Polotsky, V. Y. 2005. Disorders of glucose metabolism in sleep apnea.

Journal of Applied Physiology, 99(5): 1998-2007.

Ravesloot, M. J. L., van Maanen, J. P., Hilgevoord, A. A. J., van Wagenveld, B. A., & de Vries,

N. 2012. Obstructive sleep apnea is underrecognized and underdiagnosed in patients

undergoing bariatric surgery. European Archives Of Oto-Rhino-Laryngology: Official Journal

Of The European Federation Of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated With

The German Society For Oto-Rhino-Laryngology - Head And Neck Surgery, 269(7): 1865-

1871.

Rezaeitalab, F., Moharrari, F., Saberi, S., Asadpour, H., & Rezaeetalab, F. 2014. The

correlation of anxiety and depression with obstructive sleep apnea syndrome. Journal of

Research in Medical Sciences, 19(3): 205-210.

Rishi, M. A., Shetty, M., Wolff, A., Amoateng-Adjepong, Y., & Manthous, C. A. 2010. Atypical

antipsychotic medications are independently associated with severe obstructive sleep

apnea. Clinical Neuropharmacology, 33(3): 109-113.

Seda, G., Tsai, S., & Lee-Chiong, T. 2014. Medication effects on sleep and breathing. Clinics

in Chest Medicine, 35(3): 557-569.

Sharafkhaneh, A., Giray, N., Richardson, P., Young, T., & Hirshkowitz, M. 2005. Association of

psychiatric disorders and sleep apnea in a large cohort. Sleep, 28(11): 1405-1411.

Sharafkhaneh, A., Richardson, P., & Hirshkowitz, M. 2004. Sleep apnea in a high risk

population: a study of Veterans Health Administration beneficiaries. Sleep Medicine, 5(4):

345-350.

Smith, D. J., Langan, J., McLean, G., Guthrie, B., & Mercer, S. W. 2013a. Schizophrenia is

associated with excess multiple physical-health comorbidities but low levels of recorded

cardiovascular disease in primary care: cross-sectional study. BMJ Open, 3(4).

Smith, D. J., Martin, D., McLean, G., Langan, J., Guthrie, B., & Mercer, S. W. 2013b.

Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. *BMC Medicine*, 11(1): 263-263.

Soreca, I., Levenson, J., Lotz, M., Frank, E., & Kupfer, D. J. 2012. Sleep apnea risk and clinical correlates in patients with bipolar disorder. *Bipolar Disorders*, 14(6): 672-676.

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., & Thacker, S. B. 2000. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA: The Journal Of The American Medical Association*, 283(15): 2008-2012.

Stubbs, B., De Hert, M., Sepehry, A. A., Correll, C. U., Mitchell, A. J., Soundy, A., Detraux, J., & Vancampfort, D. 2014. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. *Acta Psychiatrica Scandinavica*.

Stubbs, B., Vancampfort, D., De Hert, M., & Alex, J. M. 2015 (in press). The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: A systematic review and comparative meta-analysis. *Acta psychiatrica Scandinavica*.

Sutherland, K., Lee, R. W. W., & Cistulli, P. A. 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: impact of ethnicity. *Respirology (Carlton, Vic.)*, 17(2): 213-222.

Thornicroft, G. 2011. Physical health disparities and mental illness: the scandal of premature mortality. *The British Journal Of Psychiatry: The Journal Of Mental Science*, 199(6): 441-442.

Van Ede, L., Yzermans, C. J., & Brouwer, H. J. 1999. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. *Thorax*, 54(8): 688-692.

Vancampfort, D., Mitchell, J. A., De Hert, M., & Stubbs, B. 2015 (in press). Prevalence and Predictors of Type 2 Diabetes in People with Bipolar Disorder: A Systematic Review and Meta-Analysis. *Journal of Clinical Psychiatry*.

Vancampfort, D., Probst, M., Stubbs, B., Soundy, A., De Herdt, A., & De Hert, M. 2014. Associations between expiratory spirometry parameters and limitations in daily life activities in patients with schizophrenia. *General Hospital Psychiatry*, 36(2): 172-176.

Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., De Herdt, A., Sienaert, P., Probst, M., & De Hert, M. 2013. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *American Journal of Psychiatry*, 170(3): 265-274.

Vozoris, N. T. 2012. Sleep apnea-plus: prevalence, risk factors, and association with cardiovascular diseases using United States population-level data. *Sleep Medicine*, 13(6): 637-644.

Walker, E. R., McGee, R. E., & Druss, B. G. 2015. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. *JAMA Psychiatry*.

Winkelman, J. W. 2001. Schizophrenia, obesity, and obstructive sleep apnea. *The Journal Of Clinical Psychiatry*, 62(1): 8-11.

Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. 1993. The occurrence of sleep-disordered breathing among middle-aged adults. *The New England Journal Of Medicine*, 328(17): 1230-1235.

Young, T., Skatrud, J., & Peppard, P. E. 2004. Risk Factors for Obstructive Sleep Apnea in Adults. *JAMA: Journal of the American Medical Association*, 291(16): 2013-2016.

- Ancoli-Israel, S., Martin, J., Jones, D. W., Caligiuri, M., Patterson, T., Harris, M. J., & Jeste, D. V. 1999. Sleep-disordered breathing and periodic limb movements in sleep in older patients with schizophrenia. *Biological Psychiatry*, 45(11): 1426-1432.
- Association, A. P. 2000. Diagnostic and Statistical Manual of Mental Disorders – DSM-IV-TR. 4th edition: American Psychiatric Association.
- Begg, C. B., & Mazumdar, M. 1994. Operating characteristics of a rank correlation test for publication bias. *Biometrics*, 50(4): 1088-1101.
- Bucks, R. S., Olaithe, M., & Eastwood, P. 2013. Neurocognitive function in obstructive sleep apnoea: A meta-review. *Respirology*, 18(1): 61-70.
- Canessa, N., Castronovo, V., Cappa, S. F., Aloia, M. S., Marelli, S., Falini, A., Alemanno, F., & Ferini-Strambi, L. 2011. Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. *American Journal Of Respiratory And Critical Care Medicine*, 183(10): 1419-1426.
- Carney, R. M., Howells, W. B., Freedland, K. E., Duntley, S. P., Stein, P. K., Rich, M. W., & Miller, G. E. 2006. Depression and obstructive sleep apnea in patients with coronary heart disease. *Psychosomatic Medicine*, 68(3): 443-448.
- Coughlin, S. R., Mawdsley, L., Mugarza, J. A., Calverley, P. M. A., & Wilding, J. P. H. 2004. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *European Heart Journal*, 25(9): 735-741.
- De Hert, M., Correll, C. U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Detraux, J., Gautam, S., Möller, H.-J., Ndeti, D. M., Newcomer, J. W., Uwakwe, R., & Leucht, S. 2011. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry: Official Journal Of The World Psychiatric Association (WPA)*, 10(1): 52-77.
- Deldin, P. J., Phillips, L. K., & Thomas, R. J. 2006. A preliminary study of sleep-disordered breathing in major depressive disorder. *Sleep Medicine*, 7(2): 131-139.
- DerSimonian R., & N., L. 1988. Meta-Analysis in Clinical Trials. *Controlled Clinical Trials*, 7: 177-188.
- Edwards, C., Mukherjee, S., Simpson, L., Palmer, L. J., Almeida, O. P., & Hillman, D. R. 2015. Depressive Symptoms before and after Treatment of Obstructive Sleep Apnea in Men and Women. *Journal Of Clinical Sleep Medicine: JCSM: Official Publication Of The American Academy Of Sleep Medicine*, 11(9): 1029-1038.
- Egger, M., Davey Smith, G., Schneider, M., & Minder, C. 1997. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)*, 315(7109): 629-634.
- El-Ad, B., & Lavie, P. 2005. Effect of sleep apnea on cognition and mood. *International Review of Psychiatry*, 17(4): 277-282.
- Farabollini, B., Braschi, M. C., & Bonifazi, F. 2009. Allergic rhinitis and associated pathologies: the rationale for steroid options. *European Annals Of Allergy And Clinical Immunology*, 41(3): 67-79.
- Fu, R., Gartlehner, G., Grant, M., Shamliyan, T., Sedrakyan, A., Wilt, T. J., Griffith, L., Oremus, M., Raina, P., Ismaila, A., Santaguida, P., Lau, J., & Trikalinos, T. A. 2011. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. *Journal Of Clinical Epidemiology*, 64(11): 1187-1197.
- Gami, A. S., Olson, E. J., Shen, W. K., Wright, R. S., Ballman, K. V., Hodge, D. O., Herges, R. M., Howard, D. E., & Somers, V. K. 2013. Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death: A Longitudinal Study of 10,701 Adults. *Journal of the American College of Cardiology (JACC)*, 62(7): 610-616.

- Gardner-Sood P, Lally J , & al, S. S. e. 2015 (in press). Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT RCT study. *Psychological Medicine*.
- Gibson, G. J. 2005. Obstructive sleep apnoea syndrome: underestimated and undertreated. *British Medical Bulletin*, 72: 49-65.
- Giles, T. L., Lasserson, T. J., Smith, B. H., White, J., Wright, J., & Cates, C. J. 2006. Continuous positive airways pressure for obstructive sleep apnoea in adults. *The Cochrane Database Of Systematic Reviews*(3): CD001106.
- Gupta, M. A., & Simpson, F. C. 2015. Obstructive sleep apnea and psychiatric disorders: a systematic review. *Journal Of Clinical Sleep Medicine: JCSM: Official Publication Of The American Academy Of Sleep Medicine*, 11(2): 165-175.
- Harris, M., Glozier, N., Ratnavadivel, R., & Grunstein, R. R. 2009. Obstructive sleep apnea and depression. *Sleep Medicine Reviews*, 13(6): 437-444.
- Hattori, M. T. T. A. M. H. Y. T. N. 2009. Risk factors for obstructive sleep apnea syndrome screening in mood disorder patients. *Psychiatry & Clinical Neurosciences*, 63(3): 385-391.
- Higgins JPT, & S, G. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
- Hrubos-Strøm, H., Einvik, G., Nordhus, I. H., Randby, A., Pallesen, S., Moum, T., Omland, T., & Dammen, T. 2012. Sleep apnoea, anxiety, depression and somatoform pain: a community-based high-risk sample. *The European Respiratory Journal*, 40(2): 400-407.
- Ioannidis, J. P. 2009. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. *CMAJ: Canadian Medical Association Journal*, 181(8): 488-493.
- JC, L., & SM, I. 2012. Obstructive sleep apnoea Metabolic consequences: pathophysiology and clinical implications. *Medicine*, April 2014, Pages 78-92.
- Johns, M. W. 1993. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. *Chest*, 103(1): 30-36.
- Kalucy, M. J., Grunstein, R., Lambert, T., & Glozier, N. 2013. Obstructive sleep apnoea and schizophrenia--a research agenda. *Sleep Medicine Reviews*, 17(5): 357-365.
- Kelly, T., Douglas, L., Denmark, L., Brasuell, G., & Lieberman, D. Z. 2013. The high prevalence of obstructive sleep apnea among patients with bipolar disorders. *Journal of Affective Disorders*, 151(1): 54-58.
- Lett, H. S., Blumenthal, J. A., Babyak, M. A., Sherwood, A., Strauman, T., Robins, C., & Newman, M. F. 2004. Depression as a Risk Factor for Coronary Artery Disease: Evidence, Mechanisms, and Treatment. *Psychosomatic Medicine*, 66(3): 305-315.
- Levine, J., Chengappa, K. N., Patel, A., Vagnucci, A., John, V., Brar, J. S., Chalasani, L., Parepally, H., & Ganguli, R. 2001. Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. *Journal Of Psychiatric Practice*, 7(6): 432-439.
- Manu, P., Kane, J. M., & Correll, C. U. 2011. Sudden deaths in psychiatric patients. *The Journal Of Clinical Psychiatry*, 72(7): 936-941.
- Medicine, A. A. o. S. 2005. The international classification of sleep disorders, 2nd ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine.
- Mitchell, A. J., Vancampfort, D., De Herdt, A., Yu, W., & De Hert, M. 2013a. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early

- schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. *Schizophrenia Bulletin*, 39(2): 295-305.
- Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. 2013b. Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis. *Schizophrenia Bulletin*, 39(2): 306-318.
- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Clinical Trials*, 6(7): 1-6.
- Muñoz, A., Mayoralas, L. R., Barbé, F., Pericás, J., & Agustí, A. G. 2000. Long-term effects of CPAP on daytime functioning in patients with sleep apnoea syndrome. *The European Respiratory Journal*, 15(4): 676-681.
- Mysliwiec, V., McGraw, L., Pierce, R., Smith, P., Trapp, B., & Roth, B. J. 2013. Sleep disorders and associated medical comorbidities in active duty military personnel. *Sleep*, 36(2): 167-174.
- Ohayon, M. M. 2003. The Effects of Breathing-Related Sleep Disorders on Mood Disturbances in the General Population. *Journal of Clinical Psychiatry*, 64(10): 1195-1200.
- Olaithe, M., & Bucks, R. S. 2013. Executive Dysfunction in OSA Before and After Treatment: A Meta-Analysis. *Sleep*, 36(9): 1297-1305.
- Ong, J. C., Gress, J. L., San Pedro-Salcedo, M. G., & Manber, R. 2009. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. *Journal of Psychosomatic Research*, 67(2): 135-141.
- organisation, W. h. 1993. The ICD-10 Classification of Mental and Behavioural Disorders – Diagnostic Criteria for Research.
- Partti, K., Vasankari, T., Kanervisto, M., Perälä, J., Saarni, S. I., Jousilahti, P., Lönnqvist, J., & Suvisaari, J. 2015. Lung function and respiratory diseases in people with psychosis: population-based study. *The British Journal Of Psychiatry: The Journal Of Mental Science*.
- Peker, Y., Carlson, J., & Hedner, J. 2006. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. *The European Respiratory Journal*, 28(3): 596-602.
- Peppard, P. E., Young, T., Palta, M., Dempsey, J., & Skatrud, J. 2000. Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA*, 284(23): 3015-3021.
- Plante, D. T., & Winkelman, J. W. 2008. Sleep disturbance in bipolar disorder: Therapeutic implications. *The American Journal of Psychiatry*, 165(7): 830-843.
- Punjabi, N. M. 2008. The epidemiology of adult obstructive sleep apnea. *Proceedings of the American Thoracic Society*, 5(2): 136-143.
- Punjabi, N. M., & Polotsky, V. Y. 2005. Disorders of glucose metabolism in sleep apnea. *Journal of Applied Physiology*, 99(5): 1998-2007.
- Ravesloot, M. J. L., van Maanen, J. P., Hilgevoord, A. A. J., van Wagenveld, B. A., & de Vries, N. 2012. Obstructive sleep apnea is underrecognized and underdiagnosed in patients undergoing bariatric surgery. *European Archives Of Oto-Rhino-Laryngology: Official Journal Of The European Federation Of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated With The German Society For Oto-Rhino-Laryngology - Head And Neck Surgery*, 269(7): 1865-1871.
- Rezaeitalab, F., Moharrari, F., Saber, S., Asadpour, H., & Rezaeitalab, F. 2014. The correlation of anxiety and depression with obstructive sleep apnea syndrome. *Journal of Research in Medical Sciences*, 19(3): 205-210.

- Rishi, M. A., Shetty, M., Wolff, A., Amoateng-Adjepong, Y., & Manthous, C. A. 2010. Atypical antipsychotic medications are independently associated with severe obstructive sleep apnea. *Clinical Neuropharmacology*, 33(3): 109-113.
- Seda, G., Tsai, S., & Lee-Chiong, T. 2014. Medication effects on sleep and breathing. *Clinics in Chest Medicine*, 35(3): 557-569.
- Sharafkhaneh, A., Giray, N., Richardson, P., Young, T., & Hirshkowitz, M. 2005. Association of psychiatric disorders and sleep apnea in a large cohort. *Sleep*, 28(11): 1405-1411.
- Sharafkhaneh, A., Richardson, P., & Hirshkowitz, M. 2004. Sleep apnea in a high risk population: a study of Veterans Health Administration beneficiaries. *Sleep Medicine*, 5(4): 345-350.
- Smith, D. J., Langan, J., McLean, G., Guthrie, B., & Mercer, S. W. 2013a. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. *BMJ Open*, 3(4).
- Smith, D. J., Martin, D., McLean, G., Langan, J., Guthrie, B., & Mercer, S. W. 2013b. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. *BMC Medicine*, 11(1): 263-263.
- Soreca, I., Levenson, J., Lotz, M., Frank, E., & Kupfer, D. J. 2012. Sleep apnea risk and clinical correlates in patients with bipolar disorder. *Bipolar Disorders*, 14(6): 672-676.
- Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., & Thacker, S. B. 2000. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA: The Journal Of The American Medical Association*, 283(15): 2008-2012.
- Stubbs, B., De Hert, M., Sepehry, A. A., Correll, C. U., Mitchell, A. J., Soundy, A., Detraux, J., & Vancampfort, D. 2014. A meta- analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. *Acta Psychiatrica Scandinavica*.
- Stubbs, B., Gardner-Sood, P., Smith, S., Ismail, K., Greenwood, K., Farmer, R., & Gaughran, F. 2015. Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis. *Schizophrenia Research*.
- Stubbs, B., Vancampfort, D., De Hert, M., & Alex, J. M. 2015 (in press). The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: A systematic review and comparative meta-analysis. *Acta psychiatrica Scandinavica*.
- Sutherland, K., Lee, R. W. W., & Cistulli, P. A. 2012. Obesity and craniofacial structure as risk factors for obstructive sleep apnoea: impact of ethnicity. *Respirology (Carlton, Vic.)*, 17(2): 213-222.
- Vancampfort, D., Mitchell, J. A., De Hert, M., & Stubbs, B. 2015 (in press). Prevalence and Predictors of Type 2 Diabetes in People with Bipolar Disorder: A Systematic Review and Meta-Analysis. *Journal of Clinical Psychiatry*.
- Vancampfort, D., Probst, M., Stubbs, B., Soundy, A., De Herdt, A., & De Hert, M. 2014. Associations between expiratory spirometry parameters and limitations in daily life activities in patients with schizophrenia. *General Hospital Psychiatry*, 36(2): 172-176.
- Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., De Herdt, A., Sienaert, P., Probst, M., & De Hert, M. 2013. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *American Journal of Psychiatry*, 170(3): 265-274.

- Vozoris, N. T. 2012. Sleep apnea-plus: prevalence, risk factors, and association with cardiovascular diseases using United States population-level data. *Sleep Medicine*, 13(6): 637-644.
- Walker, E. R., McGee, R. E., & Druss, B. G. 2015. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. *JAMA Psychiatry*.
- Wells, G., Shea, B., O'Connell, D., & Peterson, J. e. a. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
- Winkelman, J. W. 2001. Schizophrenia, obesity, and obstructive sleep apnea. *The Journal Of Clinical Psychiatry*, 62(1): 8-11.
- Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. 1993. The occurrence of sleep-disordered breathing among middle-aged adults. *The New England Journal Of Medicine*, 328(17): 1230-1235.
- Young, T., Skatrud, J., & Peppard, P. E. 2004. Risk Factors for Obstructive Sleep Apnea in Adults. *JAMA: Journal of the American Medical Association*, 291(16): 2013-2016.

Accepted manuscript

Table 1- Summary of included studies

Author	Location, setting	Population	Participant details	OSA measurement	NOS summary score
Clinical samples					
<i>Levine et al., 2001</i>	US, retrospective study	MDD (n=43), BD (n=66), Schizophrenia (n=140), Schizoaffective (n=91)	MDD 41 years, 65% male BD 42 years, 59% male Schizophrenia 41 years Consecutive psychiatric patients. 80% overall sample taking antipsychotic medication.	Diagnosed by overnight polysomnography and oxyhemoglobin desaturation	4
<i>Winkelman et al., 2001</i>	US, retrospective study	MDD (n=176) BD (n=92) Schizophrenia (n=46)	MDD 39.9±16.6 years, 51.1% male, BMI 27±8.6, 10.8% taking neuroleptics BD 38±15 years, 32.6% male, BMI 27.9 ± 7.6, 21.7% taking psychotropic medicine Schizophrenia 35.3 ± 8.4 years, 80.4% male, BMI 31.5 ± 8.2, 100% taking psychotropic medication. All patients were referred to a sleep disorder	Defined as present if the RDI exceeded 10 (or 20) apnea + hypopnea per hour of sleep	4

			consultation service from an inpatient psychiatric hospital		
<i>Deldin et al., 2005</i>	US, cross sectional	MDD (n=19)	34.47±11.52 years, 21% male, BMI 26.13±7.40, Antidepressants: 37% Sedative hypnotics: 16% Recruited through newspaper advert and part of larger trial on MDD and memory.	Polysomnography , RDI > 5 major events per hour	4
<i>Carney et al., 2006</i>	US, cross sectional	MDD (n=53)	53.8±9 years, 53% male, BMI 30.1±6.8 Participants all had stable coronary heart disease.	Polysomnography OSAHS (obstructive sleep apnea encompassing hypopnea syndrome) was a priori defined as ≥5 apneic or hypopneic episodes per hour of sleep	5
<i>Hattori M. et al., 2009</i>	Japan, cross sectional	MDD (n=19) BD (n=13)	Overall 75% sample were male, not possible to determine further participant details.	Overnight PSG plus AHI ≥5, according to the International Classification of Sleep Disorders 2nd edition (ICSD2); alternative criterion was AHI>10 for secondary analyses	4
<i>Ong JC et al., 2009</i>	US, baseline RCT data	MDD (n=51)	48.28±12.32 years, 59% male, BMI	Polysomnography ; a AHI score ≥15 was considered diagnostic for	4

			27.18±6.39 All participants had comorbid insomnia	OSA	
<i>Mysliwiec et al., 2012</i>	US, retrospective	MDD (n=164)	Overall 93% sample male, not possible to determine further participant details. Cases were recruited among active duty military personnel	PSG using the American Academy of Sleep Medicine alternative scoring method for hypopneas requiring a ≥50% decrease in the nasal pressure signal excursion from baseline lasting 10 sec or more with either a ≥3% desaturation or an arousal. OSA cases were further distinguished in "mild" ones AHI 5-15, or "moderate-to-severe" OSAs if AHI score was >15.	4
<i>Soreca I et al., 2014</i>	US, cross sectional	BD (n=28)	41.7±9.8 years, 32% male, BMI 33.8, all BD I	Objective measurement of AHI>5	4
<i>Kelly T. et al., 2013</i>	US, retrospective	BD (n=482)	44.21±17 years, 40% male, BMI 26.7±5.51 BD-I (n=58), BD-II (n=301) or BD-unclear (n=123)	Clinical sleep lab for PSG, using the standard American Academy of Sleep Medicine criteria of an apnea index of at least 15 or at least 5 with daytime hypersomnolence	4
<i>Ancoli-Israel et al., 1999</i>	US, cross sectional	Schizophrenia (n=52)	59.6±8.9 years, 67.30% male, BMI 28.5±7.4, 84.60% taking antipsychotic	The Medilog/Respitrace portable recording system was used in	4

			medication	conjunction with portable oxymetry to record sleep, RDI>10	
Population cohort studies					
<i>Sharafkhaneh et al 2005</i>	US, retrospective cohort	MDD (n= 358,817) BD (n= 71,362) Schizophrenia (n= 138,371)	Overall 90.2% of sample were male. No clear demographic data on diagnostic sub groups Inpatient records of Veteran's Health Administration from 1992–2001	Confirmed medical diagnosis of OSA based on ICD criteria	5
<i>Hrubos-Strom H et al., 2012</i>	Norway, cross sectional	MDD (n=36)	48.8±10.3 years, 65.50% male, BMI 29.1±5.2	PSG and AHI> 5 events h-1 were diagnosed with OSA following an initial screen with the Berlin sleep Screening questionnaire.	5

KEY: US=United States, MDD= Major depressive disorder, BD= bipolar disorder, RDI= respiratory disturbance index, PSG= polysomnography

Highlights

- Approximately one quarter of patients with serious mental illness had obstructive sleep apnea
- The prevalence of OSA was higher in those with MDD (36%) as compared to BD (24%) and Schizophrenia (15%)
- Similar to the general population, increasing age and BMI were predictors of OSA in patients with serious mental illness